

INTERIM REPORT

January to September 2009



 **VITA 34**

CONSOLIDATED KEY FIGURES

		07/01- 09/30/2009	07/01- 09/30/2008	01/01- 09/30/2009	01/01- 09/30/2008
STEM CELL PREPARATIONS					
Umbilical cord blood storages	Number	2,980	2,976	8,105	8,282
PROFIT / LOSS					
Revenues	EUR k	4,076	4,109	11,101	11,296
Gross profit	EUR k	2,711	2,798	7,292	7,532
EBIT	EUR k	246	-580	67	-1,709
Period result	EUR k	400	-474	404	-1,139
				09/30/2009	09/30/2008
BALANCE SHEET / CASH FLOW					
Total assets	EUR k			30,618	30,365
Equity	EUR k			18,647	18,639
Equity ratio	%			60.9	61.4
Liquid funds including other financial assets	EUR k			7,654	7,187
Capital expenditures*	EUR k	236	274	443	673
Depreciation*	EUR k	124	107	452	316
Cash flow from operating activities	EUR k	1,044	-923	25	-3,172
EMPLOYEES					
Employees (as of September 30)	Number			104	119
Personnel expenditures	EUR k			3,888	4,392

*Information for tangible and intangible assets

CONTENTS

	PAGE
LETTER TO THE SHAREHOLDERS	4
GROUP INTERIM REPORT	6
1 Summary	6
2 Revenue and Profit Situation	6
3 Financial and Asset Situation	7
4 Investments	9
5 Employees	9
6 VITA 34 on the Capital Market	9
7 Risks and Market Opportunities	10
8 Outlook	11
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS	12
1 Condensed Consolidated Income Statement	12
2 Condensed Consolidated Accumulated Income Statement	13
3 Condensed Consolidated Balance Sheet	14
4 Condensed Consolidated Statement of Cash Flows	16
5 Condensed Consolidated Statement of Changes in Equity	17
NOTES ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS	18
FINANCIAL CALENDAR AND CONTACT	21

LETTER TO THE SHAREHOLDERS

Dear Shareholders,

The positive development of the year 2009 at VITA 34 continued on in the 3rd quarter, as well. In the storage of stem cell preparations we have achieved the best results in the company's history during the reporting period. In all, in Q3 we have analyzed 2,980 preparations and subsequently stored them at negative 196 degrees Celsius in the Glass Laboratory in Leipzig. We can also be satisfied with revenues of EUR 4.1 million, especially given the ongoing difficult economic situation, which demonstrated only cautious recovery tendencies at a low level in Q3 2009.

However, we are particularly proud of the fact that VITA 34 operated profitably in this quarter, to a degree that our company is in the black on a nine-month basis. Our earnings before interest and taxes, EBIT, was EUR 0.2 million in Q3 and altogether EUR 0.1 million in the three quarters of the current fiscal year. After a slight loss in Q1 (EBIT negative EUR 0.2 million) we have been able to demonstrate the second positive quarter in a row. In this way we want to proceed and are, accordingly, more than confident that we will achieve our goal of a black zero on an EBIT basis for the year as a whole.

Once again, our Spanish partner Secuvita made a significant contribution to the positive development of our company. We store preparations for the customers of Secuvita in Leipzig. The VITA 34 "Made in Germany" quality has proven itself in the cooperation. We place emphasis on the highest standards of quality, in logistics as well as in the work in the lab and in cryo-conservation. We are of the opinion that this is the only way we can offer a medicinal preventative care service that keeps the promises it makes today over decades: The youngest and most capable adult stem cells of the best quality for the later use in the therapy of severe illnesses and in regenerative medicine.

Our stringent quality requirement is an important factor in cooperative efforts with our partners. There is a reason why no other competitor has anywhere near such a great number of clinic partners as VITA 34, which has 850. In addition, no other umbilical cord blood bank can demonstrate a comparable number of cooperative arrangements with private and compulsory health insurance companies, which currently number 40. VITA 34 defines its large lead and market-leading position not only in terms of more than 64,000 storage preparations and a market share of more than 66 percent, but also in terms of quality.

The cooperation with Secuvita shows that our approach is also successful internationally. We expanded this careful internationalization in 2009. Our services have been available to parents in Slovenia, too, as of Q1. In this EU country with more than 20,000 births annually, we are working together with our local partner Izvorna Celica d.o.o., which handles marketing and on-site training. The first preparations from Slovenia have already been stored in Leipzig, and the cooperation is developing according to our plans. In the same way, we have been addressing an additional market for VITA 34 services in Italy as of Q3, having closed a cooperative agreement with the Sorgente S.r.l. company. We will store umbilical cord blood for the Sorgente customers in Leipzig in exchange for compensation. The first preparations have already arrived at the Glass Laboratory. With some 500,000 births per annum, Italy is an attractive market, which is also well developed for umbilical cord blood banking.



Peter Boehnert (CFO), Dr. med. Eberhard F. Lampeter (CEO) and Oliver Papavlassopoulos (CMO VITA 34 AG)

VITA 34 is now present in a number of international markets, directly or indirectly, Austria, Switzerland, Spain, Italy and Slovenia. The incremental expansion of the activities will be continued in the future. Of particular interest are countries, in which the private expenditures for healthcare are above average, since our information has shown that there is an above-average acceptance for private umbilical cord blood banking.

The medical justification for the use of umbilical cord blood in the therapy of severe diseases and in regenerative medicine is documented by constantly increasing use figures. Worldwide, the number of transplantations of stem cells from umbilical cord blood in the past year was 370 percent higher than the 2006 figures, and the tendency is towards continued growth. The main areas of application were in brain damage, Type 1 diabetes and leukemia. In Germany, the research group for diabetes at the Technical University Munich under the direction of Prof. Dr. Anette-Gabriele Ziegler is currently conducting a study together with VITA 34 on the efficacy of umbilical cord blood in Type 1 diabetes. Children with Type 1 diabetes are given their own umbilical cord blood that was previously stored at VITA 34. Subsequently, the children are studied over two years and compared with a control group, that has been treated with conventional therapies. The first child was treated in March 2009. We are optimistic, that this study will confirm the very positive results of a comparable study from the USA.

Also encouraging are two independent studies from Germany and Spain, which show that stem cells from umbilical cord blood are better than all other stem cells for a so-called "reprogramming" into pluripotent stem cells. These on the other hand can be differentiated well into numerous types of cells and, above all, without possible damage. We are convinced that this advance in medicine will further increase the significance of stem cells from umbilical cord blood. VITA 34 will profit especially from this.

Leipzig, October 14, 2009

Dr. Eberhard Lampeter

Peter Boehnert

GROUP INTERIM REPORT

01/01 to 09/30/2009

1 SUMMARY

With a market share in Germany of some 66 percent when it comes to the storage of umbilical cord blood transplants, VITA 34 is the leading umbilical cord blood bank in the German-speaking countries. Moreover, VITA 34 services are offered in various configurations in additional European countries. For example, VITA 34 is represented in Spain, Slovenia, and most recently Italy, by cooperation partners. In the expansion, VITA 34 benefits from the fact that as the oldest private umbilical cord blood bank in Europe it has a great deal of experience in the entire process chain of the collection, analysis and storage of umbilical cord blood. This goes hand in hand with the change in legislation in many countries in accordance with EU specifications, which improve the market entry prerequisites for VITA 34 in additional countries.

The VITA 34 target group consists of expecting parents. They must be informed about the possibility of storage and have the justification for it explained to them, so that they are prepared to use the necessary financial resources for storage. Approaching expecting parents is, therefore, one of the keys to the further development of VITA 34. To date in Germany umbilical cord blood is only stored in some 2 percent of births. Other countries have shown that the question of money is not the primary consideration when considering storage. For example, in Greece or in several Asian countries, storages have already reached double-digit percentages.

The tanks of VITA 34 in Leipzig now store more than 64,000 umbilical cord blood preparations.


Stem cells are expected to play an increasingly greater role in the treatment of diseases and in regenerative medicine in the future. Thus, the product range offered by VITA 34 should increasingly enter the focus of the general public. This will result in additional growth potential for the company, which will be additionally rounded out by the expansion in Europe.

In addition, VITA 34 is opening up potential revenues with product differentiation. Solutions tailored to different customer groups are being offered with regard to the scope of the offer, as well as the payment modalities. The VITA 34 max product deserves special mention. Here, additional screenings are performed on the collected umbilical cord blood to detect a genetic predisposition for various diseases.

2 REVENUE AND PROFIT SITUATION

In Q3 2009 2,980 stem cell preparations were stored at VITA 34. This is the highest number of storages in a quarter since the founding of the company and it easily exceeds the prior best figure of Q3 2008 of 2,976. In all, there were 8,105 storages in the first three quarters of 2009. This was roughly the level of the same period in the prior year, in which 8,282 stem cell preparations were stored. The business in Spain, covered by cooperation partner Secuvita, showed continued growth.

VITA 34 books revenues some one to two months after the storage of a transplant. Storages, therefore, precede the development of revenues. In Q3 2009 VITA 34 earned revenues totaling EUR 4.1 million, thus attaining the level of the prior year's quarter, in which EUR 4.1 million in revenues were also generated. For the first three quarters of 2009 revenues were EUR 11.1 million, following EUR 11.3 million in the prior year's period. Here, it should be noted that the share of storages for Spanish cooperation partner Secuvita continued to rise. This generates lower revenues per storage, since parts of the service are booked as revenues at Secuvita.



Gross profit in Q3 2009 was EUR 2.7 million and, therefore, was only slightly below the value of Q3 2008, when EUR 2.8 million were generated. EUR 7.3 million were posted for the first three quarters of 2009, following EUR 7.5 million in the corresponding time period the previous year.

There was a clear and planned reduction in marketing and sales expenditures in Q3 2009. EUR 2.0 million were expended following EUR 2.6 million in Q3 of the prior year. There were also significantly lower expenditures of EUR 5.8 million here in the first three quarters than in the previous year's period when they were EUR 7.6 million. This reduction was the result of an optimization in sales that led to noticeable increases in efficiency. Administrative costs in Q3 2009 of EUR 0.6 million were slightly lower than in the prior year's quarter, in which they were EUR 0.7 million. EUR 1.8 million were posted for the first 9 months of 2009, a value, which was slightly lower than the comparative figure of EUR 2.0 million of the prior year.

The income tax expenditure in Q3 2009 was EUR 55k, following an income tax credit of EUR 117k in the prior years' period. For the first three quarters an income tax credit of EUR 37k was booked, which was significantly lower than the same three quarters of the prior year when it was EUR 409k. The credit was mainly the result of deferred taxes according to IFRS.

Altogether the profit from continued operations in Q3 2009 improved significantly from a loss of EUR -0.5 million the prior year to EUR 0.4 million. Thus, for the first three months of 2009, VITA 34 also posted a profit of EUR 0.4 million. In the corresponding time period the prior year, the loss was still at EUR -1.4 million. Last year a profit in the amount of EUR 0.2 million was generated from the discontinued business operations in the USA, whereas in this year there was no contribution to profit from the discontinued business unit. Accordingly, the period result the prior year was EUR -1.1 million.

3 FINANCIAL AND ASSET SITUATION

Financial Situation

In Q3 2009, VITA 34 was able to increase cash and cash equivalents to EUR 7.7 million. Thus, the cash and cash equivalents were higher than the figure for the prior year, when EUR 7.3 million were posted as of September 30th, and they were more than on hand at the end of Q2 when it was EUR 6.6 million. Consequently, cash and cash equivalents at the end of Q3 were some EUR 2.89 per share. The increase in liquidity in Q3 was EUR 1.1 million. The cash flow from operations in Q3 2009 was EUR 1.0 million. In the first three quarters of 2009 there was a positive cash flow from operations of EUR 25k, following a negative cash flow in the prior year's period of EUR -3.2 million. The increase in receivables in the first three quarters of 2009 had a negative effect of EUR -0.2 million.

The cash flow from investing activities was EUR -1.1 million after 9 months of 2009. This was primarily the result of the acquisition of short-term financial assets of EUR 1.0 million. Investments in plant and equipment were unchanged compared to the prior year's period at EUR 0.4 million, the investments in intangible assets were reduced to EUR 0.1 million following EUR 0.3 million in the first three quarters of 2008. Cash flow from financing activities was EUR 0.3 million after the first three quarters of 2009.

Assets

Unchanged, VITA 34 has a solid balance sheet structure. The equity ratio moved to a high level of 60.9 percent at the end of Q3 2009, thus showing a slight improvement as compared with the year-end level at the end of 2008. The balance sheet total at the end of the reporting period was EUR 30.6 million, remaining nearly the same as compared with the total of EUR 30.3 million at the end of 2008.

The first preparations from Slovenia and Italy have already been stored at VITA 34.

The largest item on the asset side was the goodwill of VITA 34 AG, which was posted unchanged on the balance sheet of VITA 34 at EUR 11.9 million. In all, the non-current assets were EUR 19.4 million. Plant and equipment accounted for EUR 3.2 million following EUR 3.1 million at the end of 2008.


Among the current assets totaling EUR 11.2 million, cash and cash equivalents of EUR 7.7 million represented the largest item. The comparative value at the end of 2008 was EUR 7.3 million. Receivables on the other hand rose to EUR 2.1 million following EUR 1.6 million at year's end 2008.

On the liabilities side at the end of Q3 equity of EUR 18.6 million remained unchanged the largest item. The growth as compared to the 2008 year-end value mainly resulted from the annual surplus generated in 2009 and gains from increases in the price of shares in Cord

Blood America Inc., which were booked into equity. The registered capital remained unchanged at EUR 2.6 million.

The non-current liabilities and deferred income were nearly unchanged at the end of Q3 2009 with EUR 8.7 million, compared with the value of EUR 8.6 million at year's end 2008. Deferred income, on the other hand, increased from EUR 5.4 million to EUR 5.6 million. This item contains storage fees pre-paid by customers, which are dissolved and booked as income over the course of the storage term.

Non-current liabilities and deferred income showed a slight decrease at the end of Q3 2009 to EUR 3.3 million, following EUR 3.6 million at year's end 2008. This was mainly due to lower payables, which were EUR 0.7 million as of September 30, 2009, after having been EUR 1.1 million at the end of 2008



¹ Including Other financial assets

² Excluding Deferred income



4 INVESTMENTS

VITA 34 made investments in plant and material and intangible assets in the amount of EUR 0.2 million in Q3 2009. At EUR 0.4 million, less was expended in the first nine months of 2009 than in the same period the prior year, in which investments were EUR 0.7 million. The investments in the reported period were mainly in new acquisitions in the laboratory and in expanding the cryo and storage capacities at the company's headquarters in Leipzig. Moreover, in the IT area, VITA 34 acquired and installed additional process software. It is expected that there will be no significant change in investment activity in the coming quarter.

5 EMPLOYEES

As of September 30, 2009 VITA 34 employed 104 people (without trainees and temporary workers) in the group. As compared to September 30, 2008 this meant a reduction of the number of employees by 15 as a result of headcount adjustments.

At the end of Q3 there were 24 employees in the Commercial department, 44 in Production and Quality Assurance, and 36 employees in Marketing and Sales. Based on an internal restructuring 10 persons from the Marketing and Sales department were assigned to Production and Control at the beginning of the year.

6 VITA 34 ON THE CAPITAL MARKET


After the collapse precipitated by the financial market crisis, as of Q3 2009 there have been initial signs of economic stabilization. With this as a backdrop, the stock markets worldwide are trending more positively. For example, the German Stock Index DAX gained 18 percent in value during this period, and thus also rose 18 percent in the first 18 months.

The SDAX, an indicator for German small cap stocks improved by 20 percent in Q3. Thus, the SDAX has demonstrated a plus of some 25 percent since the beginning of the year.

The VITA 34 shares were able to improve significantly in the first six months of 2009, with a share price increase of some 47 percent. Consequently, the share price showed a much better performance than either the SDAX or the DAX. The VITA share price increased in value by 13 percent in Q3 2009: From EUR 3.90 at the end of the first half year, the price per share on the Xetra electronic trading system rose to EUR 4.40 at the end of September. The stock reached its high of EUR 5.33 in Q3 on July 23rd. The low of EUR 4.20 was noted at the beginning of the quarter.

In the first nine months of 2009, the average volume of shares traded decreased slightly as compared to the volume achieved in 2008. Per day 2,348 shares were traded on all German exchanges. Of these, a majority or 2,007 were on Xetra, which represented the most liquid exchange. In Q3 2009 an average of 2,127 VITA 34 shares were traded per day on all German exchanges, and an average of 1,649 were traded on XETRA. As Designated Sponsor for VITA 34, ICF Kursmakler AG ensures tight margins between bid and offer prices, thus increasing the attractiveness of the stock for investors.

There were no changes in the fundamental shareholder structure: The percentage of VITA shares held by founders and management continues to be 15.0 percent. The largest single shareholder since the IPO has been the American health insurance company Independence Blue Cross with a share of 20.7 percent. Landesbank Baden-Württemberg holds 15.8 percent. Freefloat according to the Deutsche Börse AG definition was 48.5 percent.



On July 15, 2009, the General Shareholders' Meeting of VITA 34 International AG in Leipzig approved all agenda items with more than 99 percent. Among other things, the General Shareholders Meeting resolved to reduce the Supervisory Board from six to three members. Richard J. Neeson, Senior Vice President of large shareholder Independence Blue Cross and Dr. Uwe Marx, Director of Probiogen AG, were confirmed. Dr. Holger Födisch, Director of Dr. Födisch Umweltmesstechnik AG, was newly elected to the Supervisory Board. Altogether up to 69 percent of the capital was represented at the General Shareholders' Meeting.

VITA 34 is not only listed in the Prime Standard segment, the quality segment, of Deutsche Börse AG. The company has earned a very good reputation on the capital market for detailed and transparent communication. VITA 34 will maintain this in the future, as well. In September 2009 the Management Board demonstrated the Glass Laboratory with all

steps in the storage of umbilical cord blood to renowned subject matter and financial journalists on site in Leipzig, and explained the prospects for the company and for stem cells from umbilical cord blood. In addition, VITA 34 will present itself as usual at important capital market conferences such as the German Equity Forum in November 2009.

In-depth information of the development of business and on the VITA 34 stock can be found on the company's home page www.vita34.de, in the Investor Relations Section. VITA 34 is always available for investor questions via email at ir@vita34.de.

7 RISKS AND MARKET OPPORTUNITIES

In Q3 2009 the risks and market opportunities for VITA 34 have not changed significantly from those contained in the 2008 Annual Report.

INFORMATION AND KEY FIGURES ON THE SHARES

Ticker symbol / Reuters symbol	V3V / V3VGn.DE
Securities number / ISIN	A0BL84 / DE000A0BL849
Initial quotation	03/27/2007
Market segment	Prime Standard
Index	CDAX, Prime All Share, Technology All Share, Prime IG Biotechnology
Opening / High / Low / Closing price 3 rd quarter 2009 (Xetra)	3.00 EUR / 5.33 EUR / 2.11 EUR / 4.40 EUR
Number of shares issued	2,646,500
Freefloat as of 09/30/2009	48.5%
Market capitalization as of 09/30/2009	11. Mio. EUR
Designated Sponsor	ICF Kursmakler AG

At VITA 34 stored umbilical cord blood was applied five times in 2009.

8 OUTLOOK

Despite continuing uncertainty concerning future economic development, VITA 34 expects to achieve moderate growth between the years 2008 and 2010. For 2009, revenues are expected to be roughly the same as the prior year. The declared return to black figures on an EBIT basis, declared since the IPO in March 2007, is affirmed for the current year. An increase in profitability is expected for the year 2010.


In addition, in the coming quarters, VITA 34 expects positive effects from already closed international cooperation agreements. In the coming months the possibilities for further, careful internationalization will be reviewed on an ongoing basis. In Germany, the intent is to further expand our cooperative agreements with health insurance companies. Promising discussions have already been conducted with various health insurers. Moreover, the marketing of additional services, such as pre-screening tests for the early detection of genetic anomalies, offered since 2009, will be accelerated. Whereas in new business already more than every fourth customer takes advantage of these additional offers, in the future existing customers will be increasingly approached.

VITA 34, which has a market leading position by a large margin amongst the private German umbilical cord blood banks, is confident that it can assert itself in the future. VITA 34 should, accordingly, profit in an above average manner from positive impetus, not least thanks to the successful use of stem cell preparations made from umbilical cord blood.

Leipzig, October 14, 2009
Management Board of VITA 34 International AG



Dr. Eberhard Lampeter



Peter Boehnert

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

09/30/2009

1 CONDENSED CONSOLIDATED INCOME STATEMENT

EUR K	NOTE	07/01- 09/30/2009	07/01- 09/30/2008	01/01- 09/30/2009	01/01- 09/30/2008
Continuing operations					
Revenues		4,076	4,109	11,101	11,296
Cost of sales		-1,365	-1,311	-3,809	-3,764
Gross profit		2,711	2,798	7,292	7,532
Other operating income		152	112	494	609
Selling expenses		-1,954	-2,633	-5,834	-7,625
Administrative expenses		-649	-699	-1,803	-2,000
Other operating expenses		-14	-158	-82	-225
Net operating income		246	-580	67	-1,709
Finance revenues	4	266	133	472	369
Finance costs		-57	-144	-172	-456
Earnings before taxes		455	-591	367	-1,796
Income tax expense (income tax income)	5	-55	117	37	409
Profit from continuing operations		400	-474	404	-1,387
Discontinued operation					
Profit from discontinued operations		0	0	0	248
Period result		400	-474	404	-1,139
Earnings per share, basic / diluted (EUR)		0.15	-0.18	0.15	-0.43
Earnings per share from continuing operations, basic / diluted (EUR)		0.15	-0.18	0.15	-0.52

2 CONDENSED CONSOLIDATED ACCUMULATED INCOME STATEMENT

EUR K	NOTE	07/01- 09/30/2009	07/01- 09/30/2008	01/01- 09/30/2009	01/01- 09/30/2008
Period result		400	-474	404	-1.139
Change not affecting income		-7	13	-7	-10
Change affecting income		0	0	0	0
Income tax		0	0	0	0
Change due to a difference arising from currency translation		-7	13	-7	-10
Change not affecting income		101	-96	101	-171
Change affecting income		0	96	0	171
Income tax		0	0	0	0
Change in the amount recorded in equity (financial assets available for divestiture)		101	0	101	0
Other earnings after taxes		494	-461	498	-1.149
Period result					
Of which allotted to shareholders of the parent company		400	-474	404	-1.139
Of which allotted to non-controlling shareholders		0	0	0	0
Other earnings after taxes					
Of which allotted to shareholders of the parent company		494	-461	498	-1.149
Of which allotted to non-controlling shareholders		0	0	0	0

3 CONDENSED CONSOLIDATED BALANCE SHEET (ASSETS)

EUR K	NOTE	09/30/2009	12/31/2008
Non-current assets			
Goodwill		11,911	11,911
Intangible assets		752	930
Property, plant and equipment		3,219	3,054
Investments		127	26
Other financial assets		35	35
Deferred tax assets		775	736
Non-current trade receivables		1,806	1,996
Restricted Cash		820	1,068
		19,445	19,756
Current assets			
Inventories		554	584
Trade receivables		2,071	1,600
Other receivables and assets		894	1,118
Short-term investments		1,000	876
Other financial assets		1,000	0
Cash and cash equivalents	3	5,654	6,374
		11,173	10,552
		30,618	30,308

3 CONDENSED CONSOLIDATED BALANCE SHEET (LIABILITIES)

EUR K	NOTE	09/30/2009	12/31/2008
Equity			
Issued capital		2,647	2,647
Capital reserves		23,236	23,192
Revenue reserves		-7,330	-7,734
Other reserves		94	0
		18,647	18,105
Non-current liabilities and deferred income			
Interest-bearing loans		1,438	1,500
Silent partners' interests		940	940
Deferred grants		697	741
Deferred income		5,608	5,405
		8,683	8,586
Current liabilities and deferred income			
Trade payables		706	1,087
Silent partners' interests		516	497
Provisions		1	105
Income tax liabilities		203	208
Interest-bearing loans		125	125
Deferred grants		70	81
Other liabilities		1,048	993
Deferred income		619	521
		3,288	3,617
		30,618	30,308

4 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

EUR K	NOTE	01/01- 09/30/2009	01/01- 09/30/2008
Cash flow from operating activities			
Earnings before taxes		367	-1,796
Adjusted for:			
Amortization and depreciation		452	316
Profit / loss from disposal of non-current assets		5	0
Other non-cash expenses and income		-339	-56
Exchange differences		-9	-12
Finance revenues		-472	-369
Finance expenses		172	456
Expenses of stock-based compensation		44	59
Cash flow from ordinary operations:			
+/- Trade receivables and other receivables and assets		-220	-1,228
+/- Inventories		30	-27
+/- Trade payables and other liabilities		-142	-625
+/- Provisions		-4	-131
+/- Deferred income		301	392
Interest paid		-153	-138
Income taxes paid		-7	-13
Cash flow from operating activities		25	-3,172
Cash flow from investing activities			
Purchase of intangible assets		-81	-287
Purchase of property, plant and equipment		-362	-386
Purchase of short-term financial asset		-1,000	0
Proceeds from sale of short-term investments		0	1,000
Interest received		348	317
Cash flow from investing activities		-1,095	644
Cash flow from financing activities			
Changes in restricted cash		248	0
Proceeds from investment subsidies		163	0
Loan redemption		-62	-151
Cash flow from financing activities		349	-151
Net change in cash and cash equivalents from continued operations		-721	-2,679
Net change in cash and cash equivalents		-721	-2,679
Cash and cash equivalents at the beginning of the reporting period		6,374	9,002
Net foreign exchange difference		1	2
Cash and cash equivalents at the end of the reporting period	3	5,654	6,325
Short-term investments		1,000	862
Liquid funds		6,654	7,187

5 CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

				ACCUMULATED OTHER RESULT		
EUR K	ISSUED CAPITAL	CAPITAL RESERVE	REVENUE RESERVE	CURRENCY TRANSLATION	AVAILABLE-FOR- SALE ASSETS	TOTAL EQUITY
January 1, 2008	2,647	23,116	-6,022	-12	0	19,729
Transaction costs		2				2
Stock-based compensa- tion		57				57
Total period result	0	0	-1,139	-10	0	-1,149
September 30, 2008	2,647	23,175	-7,161	-22	0	18,639
January 1, 2009	2,647	23,192	-7,734	0	0	18,105
Stock-based compensa- tion		44				44
Total period result	0	0	404	-7	101	498
September 30, 2009	2,647	23,236	-7,330	-7	101	18,647

NOTES ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1 COMPANY INFORMATION

The parent company VITA 34 International AG (the "Company") headquartered in Leipzig (Germany), Deutscher Platz 5 a, registered under HRB 20339 in the Commercial Register of the Leipzig District Court, is purely a holding company, which has a management and financing function for its subsidiary companies. Its subsidiary companies (referred to along with the Company as "Group") are active in the field of umbilical cord blood storage. The purpose of the company is the storage, production or distribution of stem cell and blood products for therapeutic and transplantation purposes or comparable objects of business.

The unaudited, abbreviated, consolidated interim financial statements for the period from January 1 until September 30, 2009 were approved for publication by the Management Board on July 14, 2009.

2 ACCOUNTING AND VALUATION PRINCIPLES

2.1 Basis for the Preparation of the Financial Statements

The preparation of the group interim financial statements for the period from January 1 until September 30, 2006 has been conducted in accordance with IAS 34 "Interim Financial Reporting."

The group interim financial statements do not contain all of the explanations and information prescribed for the annual financial statements and should be read in conjunction with the group financial statements as of December 31, 2008.

2.2 Significant Accounting and Valuation Methods

The accounting and valuation methods used to prepare the group interim financial statements correspond with the methods used in the preparation of the group financial statements for the fiscal year as of December 31, 2008.

The group used the following new and revised IFRS standards and interpretations for the first time as of January 1, 2009:

- :: Amendments to IFRS 1 and IAS 27: Acquisition Costs for a Participation in a Subsidiary Company, Jointly Managed Companies or Associated Companies
- :: Amendments to IFRS 2: Share-Based Compensation
- :: Amendments to IAS 1: Presentation of the Financial Statements
- :: Amendments to IAS 23: Debt Capital Costs
- :: Amendments to IAS 32 and IAS 1: Puttable instruments and obligations arising on liquidation
- :: Change to IAS 39 Reclassification of Financial Assets: Effective date and transitional regulations
- :: IFRIC 12: Service Concession Agreements
- :: IFRIC 13: Customer Loyalty Programs
- :: IFRIC 14: The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction
- :: Improvements to IFRS 2008

The standards and interpretations required to be used for the first time starting January 1, 2009 (IFRIC 12 already as of January 1, 2008) resulted in no significant effects on the interim financial statements of VITA 12 International AG.

3 CASH AND CASH EQUIVALENTS

For the purposes of the consolidated statement of cash flows, the cash and cash equivalents consist of the following:

CASH AND CASH EQUIVALENTS	09/30/2009	09/30/2008
	EUR K	EUR K
Cash at banks and in hand	5,654	6,325
	5,654	6,325

4 FINANCE REVENUE

Income from mostly written off loans and loans with a conversion option into shares of Cord Blood America Inc. in the amount of EUR 239k are listed under financial income. The income is the result of the repayment by Cord Blood America Inc. of loans extended in the amount of EUR 242k.

5 INCOME TAXES

The significant components of the income tax expenditures listed in the condensed consolidated income statement consist of the following:

MAJOR COMPONENTS OF THE INCOME TAX INCOME / EXPENSE	01/01-09/30/2009	01/01-09/30/2008
CONSOLIDATED INCOME STATEMENT	EUR K	EUR K
Current income tax		
Current income tax expense	3	12
Deferred income tax		
Origination and reversal of temporary differences	-19	3
On unused tax losses	-21	-424
Income tax income	-37	-409

6 SEGMENT REPORTING

The company currently has only one business segment subject to reporting, since the group is exclusively involved in the storage of umbilical cord blood.

6.1 Information Concerning Geographic Regions

The company earns its income exclusively in Europe. Here, in the period from January 1 to September 30, 2009 income of EUR 9,428k (January 1 to September 30, 2008: EUR 9,679k) was earned in the geographic region of Germany, Austria and Switzerland, and in the Spain region income of EUR 1,673k (January 1 to September 30, 2008: EUR 1,617k) was earned.

The income was assigned to the geographic regions, taking the revenues achieved in the respective countries into consideration.

6.2 Information Concerning Important Customers

Income with a single external customer is listed under group income, which exceeds 10% of the income of the group. Income in the period from January 1 to September 30, 2009 was EUR 1,673k (January 1 to September 30, 2008: EUR 1,617k).

7 INFORMATION ON RELATIONSHIPS TO FRIENDS AND FAMILY

The following table contains the total amounts arising from transaction between friends and family in the period from January 1 to September 30, 2009 and 2008:

EXPENSES TO RELATED PARTIES	TOTAL AMOUNT OF TRANSACTIONS	
PERIOD FROM 01/01 – 09/30	2009	2008
	EUR K	EUR K
A member of the Supervisory Board is Chairman of the U.S. law offices Dillworth Paxon. Law services were purchased from Dillworth Paxon for the following amounts:	0	4
Compensation of key management personnel of the Group:		
Short-term benefits::		
- Remuneration of the Supervisory Board	49	45
- Management Board salaries	455	401
Other long-term benefits:		
- The Management Board of VITA 34 AG	0	73
Share-based compensation		
- The Managements Board of VITA 34 AG	44	56

FINANCIAL CALENDAR 2009

2009

April 15, 2009	Publication of Q1 Report
July 14, 2009	Publication of Q2 Report
July 15, 2009	Annual General Meeting
October 14, 2009	Publication of Q3 Report
November 10, 2009	German Equity Forum

CONTACT

Peter Boehnert
VITA 34 International AG
Deutscher Platz 5
04103 Leipzig

Telephone: +49 341 48792-31
Fax: +49 341 48792-39
E-Mail: ir@vita34.de

Press:

Axel Mühlhaus/Dr. Sönke Knop
edicto GmbH
Zeißelstraße 19
60318 Frankfurt

Telephone: +49 69 905505-52
Fax: +49 69 905505-77
E-Mail: vita34@edicto.de

This Interim Report was published in German and English on October 14, 2009 and is available for download on our internet site.

VITA 34 on the Internet: www.vita34.de

VITA 34 International AG

Deutscher Platz 5
04103 Leipzig

Telephone: +49 341 48792-40
Fax: +49 341 48792-39

Internet: www.vita34.de
E-Mail: ir@vita34.de

